Table 3.
Spectrum of COVID19 vaccine associated neurological disorders (Co-VAN).
| Overall |
CNS Demyelination |
GBS |
Stroke |
Encephalitis |
Myositis |
|
|---|---|---|---|---|---|---|
| Number of cases (%) | 51 | 39 (76.5) | 3 (5.9) | 6 (11.8) | 2 (3.9) | 1 (2.0) |
| Demographics | ||||||
| Mean Age(±SD) | 40.1 (14.5) | 37.8 (12.6) | 44.3(10.5) | 51.1(22.6) | 37.5(20.5) | |
| Age group < 25 years | 8 (15.7) | 6 (15.4) | – | 1(16.7) | 1 [50] | – |
| Age group 25–45 years | 26 (51.0) | 23 (59.0) | 2(66.7) | 1(16.7) | – | – |
| Age group 46–60 years | 14 (27.5) | 9 (23.1) | 1(33.3) | 2(33.3) | 1 [50] | 1 |
| Age group > 60 years | 3 (5.9) | 1 (2.3) | – | (33.3) | – | – |
| Female/Male | 27/24 | 22/17 | 2/1 | 1/5 | Both females | Male |
| Female: Male | 1.13:1 | 1.29:1 | 2:1 | 0.2:1 | ||
| Vaccine details | ||||||
| COVIShield (ChAdOx1)(%) | 43 (84.3) | 35 (89.7) | 3 [100] | 3 (50.0) | 2 [100] | 0 |
| COVAXIN (BBV152) (%) | 8 (15.7) | 4 (10.3) | 0 | 3 (50.0) | 0 | 1 [100] |
| First dose (%) | 37 (72.5) | 29(74.4) | 2(66.7) | 4(66.7) | 1(50.0) | 1 [100] |
| Second dose (%) | 14 (27.5) | 10(25.6) | 1(33.3) | 2(33.3) | 1(50.0) | – |
| Timelines | ||||||
| Mean interval from last dose (in days ± SD) | 13.2 (10.7) | 14.6 (11.6) | 13.(5.8) | 8.2 (5.6) | 5.5(2.1) | – |
| Median interval (days) from first dose (IQR) | 14 (5.5–15) | 14 | 9.5 | 9.5 | – | – |
| Median interval (days) from second dose (IQR) | 12 (3.3–14) | 14 | 14 | 6.0 | – | – |
| 1st week | 14 (27.5) | 9 (23.1) | 1(33.3) | 2(33.3) | 1 | – |
| 2nd week | 20 (39.2) | 17 (43.6) | 1(33.3) | 2(33.3) | 1 | – |
| 3rd week | 6 (11.8) | 3 (7.7) | 1(33.3) | 1(16.7) | – | – |
| 4th week | 1 (2.0) | 1 (2.6) | – | 0 | – | – |
| >4 week | 10 (19.6) | 9 (23.1) | 1(33.3) | 1(16.7) | – | – |
| Mean duration of disease (in days ± SD) | 29.5(52.9) | 26.4(24.8) | 13.3(5.8) | 2.2(1.2) | – | – |
| Causality label | ||||||
| Probable (%) | 48(94.1) | 39 [100] | 3 [100] | 4(66.7) | 1 [50] | 1 |
| Possible (%) | 3(5.9) | – | – | 2(33.3) | 1 [50] | – |
| Clinical outcomes | ||||||
| Favourable (mRS 0–1) (%) | 25 (49.0) | 21 (53.8) | 1 (33.3) | 1 (16.7) | 1 [50] | – |